Kanamycin sulfate

产品说明书

Print
Chemical Structure| 25389-94-0 同义名 : Kanamycin A sulfate; Kanamycin A(sulfate); Ophtalmokalixan; Kanamycin monosulfate; Kanamycin(sulfate)
CAS号 : 25389-94-0
货号 : A122807
分子式 : C18H38N4O15S
纯度 : >680 u/mg
分子量 : 582.577
MDL号 : MFCD00070253
存储条件：

Pure form Sealed in dry,2-8°C

In solvent -20°C:3-6个月-80°C:12个月
溶解度 :

H2O: 25 mg/mL(42.91 mM)
动物实验配方：
生物活性
描述 Kanamycin sulphate (KS) is a Mycobacterium tuberculosis protein synthesis inhibitor. KS is polycationic, a property responsible for KS poor oral absorption half-life (2.5 h) and rapid renal clearance, which results in serious nephrotoxicity/ototoxicity[3]. Animal model of acute deafness induced by a single dose of kanamycin sulfate in combination with ethacrynic acid or furosemide in guinea pig was usually used to investigate the mechanism of cochlear cell degeneration[4]. The neurons damage of the DCN (dorsal cochlear nucleus) caused by kanamycin was reversible and autophagy was upregulated in the neurotoxic course of kanamycin on DCN[5]. Moreover, with perfusion of kanamycin 10 mM in the endolymphatic space, the EP (endocochlear dc potential) declined severely[6].
临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT02496572 - Unknown April 2016 Uzbekistan ... 展开 >> Outpatient clinics in three districts Nukus, Karakalpakstan, Uzbekistan 收起 <<
NCT02975570 Tuberculosis Multi Drug Resist... 展开 >>ant Active 收起 << Phase 3 Withdrawn(The study could not ... 展开 >>be conducted since funding was not obtained.) 收起 << August 2022 -
NCT03237182 Tuberculosis, Multidrug-Resist... 展开 >>ant 收起 << Phase 4 Recruiting December 2021 South Africa ... 展开 >> King Dinuzulu Hospital Recruiting Durban, Kwa-Zulu Natal, South Africa Contact: Nesri Padayatchi, MBcHB    0312604550    nesri.padayatchi@caprisa.org    Contact: Resha Boodhram, BTech    0828383651    resha.boodhram@caprisa.org 收起 <<
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

1.72mL

0.34mL

0.17mL

8.58mL

1.72mL

0.86mL

17.17mL

3.43mL

1.72mL
参考文献

[1]Fan GR, Yin ZD, et al. Reversible neurotoxicity of kanamycin on dorsal cochlear nucleus. Brain Res. 2013 Jan 17. pii: S0006-8993(13)00068-1.

[2]Adams E, Dalle J, et al. Analysis of kanamycin sulfate by liquid chromatography with pulsed electrochemical detection. J Chromatogr A. 1997 Apr 4;766(1-2):133-9.

[3]Walker EH, Pacold ME, Perisic O, et al. Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol Cell. 2000;6(4):909-19

[4]Yin Z, Kng W. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2012;26(10):478–480.

[5]Fan GR, Yin ZD, Sun Y, et al. Reversible neurotoxicity of kanamycin on dorsal cochlear nucleus. Brain Res. 2013;1502:30–46.

[6]Komune S, Snow JB Jr. Ototoxicity of kanamycin sulfate and the barriers in the inner ear. Otolaryngol Head Neck Surg. 1981;89(6):1013–1018.